1. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity;Amano;Cytoskeleton,2010
2. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study;Ascierto;Lancet Oncol.,2013
3. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma;Atefi;Mol. Cancer,2015
4. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1;Barbie;Nature,2009
5. J.C. Bendell, K. Papadopoulos, S.F. Jones, E. Barrett, K. Guthrie, C.L. Kass, et al., Phase 1 dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors. AACR-NCI-EORTC (abstr B243).